Verrica Pharmaceuticals Inc. (VRCA)

US — Healthcare Sector
Peers: LIAN  IVA  EWTX  VIGL  CNTB  ABOS  ETON  NUVB  ELDN  VRNA  GRTX  ARQT  PLX  KDNY  DICE  PLRX  CRNX  ASND  FENC  LRMR  FIXX 

Automate Your Wheel Strategy on VRCA

With Tiblio's Option Bot, you can configure your own wheel strategy including VRCA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol VRCA
  • Rev/Share 0.0757
  • Book/Share -0.1959
  • PB -3.0372
  • Debt/Equity -0.7873
  • CurrentRatio 1.3428
  • ROIC -2.1028

 

  • MktCap 55022896.0
  • FreeCF/Share -0.5661
  • PFCF -1.0249
  • PE -0.855
  • Debt/Assets 0.3467
  • DivYield 0
  • ROE 3.4829

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now
VRCA
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Verrica Pharmaceuticals (VRCA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Read More
image for news Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.
VRCA
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Noah L. Rosenberg, M.D., as Chief Medical Officer.

Read More
image for news Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.

About Verrica Pharmaceuticals Inc. (VRCA)

  • IPO Date 2018-06-15
  • Website https://www.verrica.com
  • Industry Biotechnology
  • CEO Dr. Jayson M. Rieger M.B.A., Ph.D.
  • Employees 71
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.